Journal Home > Volume 11 , Issue 4
Food Science and Human Wellness 2022, 11(4): 765-770 https://doi.org/10.1016/j.fshw.2022.03.002
Review Article | Open Access | Issue | Published: 28 April 2022

Green tea, epigallocatechin gallate and the prevention of Alzheimer's disease: Clinical evidence

Show Author's Information Klaus W. Lange( ),  Katharina M. Lange,  Yukiko Nakamura
Department of Experimental Psychology, University of Regensburg, Regensburg 93040, Germany
Keywords:
Prevention, Neurodegeneration, Alzheimer's disease, Green tea, Epigallocatechin gallate
Cite this article:
Lange KW, Lange KM, Nakamura Y. Green tea, epigallocatechin gallate and the prevention of Alzheimer's disease: Clinical evidence. Food Science and Human Wellness, 2022, 11(4): 765-770. https://doi.org/10.1016/j.fshw.2022.03.002
Download citation
EndNote(RIS)
BibTeX

391

Views

47

Downloads

Citations

16

Crossref

11

WoS

13

Scopus

0

CSCD

Abstract Full text About this article

Given its increasing global prevalence, Alzheimer's disease (AD) has become a major public health challenge worldwide. The symptomatic treatments available for AD have shown no significant efficacy, and no disease-modifying interventions are capable of slowing the progression of the disorder. The potential of lifestyle-related factors, including diet, is increasingly recognized as an important consideration in the primary prevention of AD. Numerous mechanisms potentially underlying neuroprotective effects of bioactive components contained in tea, such as (–)-epigallocatechin-3-gallate, as well as their preventive efficacy against AD, have been elucidated in preclinical studies. However, in contrast to the abundance of mechanistic findings in animals, clinical results demonstrating efficacy in humans are scarce. While epidemiological studies have provided some evidence indicating that green tea consumption is associated with a reduced risk of age-related cognitive decline and AD, a causal relationship cannot be established on the basis of these observations. The clinical evidence regarding preventive or therapeutic effects of green tea and its bioactive components is unsatisfactory. A role of green tea in the prevention of AD cannot be recommended until well-designed, randomized, placebo-controlled clinical trials using standardized formulations confirm the purported beneficial effects of green tea.


menu
Abstract
Full text
Outline
About this article

Green tea, epigallocatechin gallate and the prevention of Alzheimer's disease: Clinical evidence

Show Author's information Klaus W. Lange( ), Katharina M. Lange, Yukiko Nakamura
Department of Experimental Psychology, University of Regensburg, Regensburg 93040, Germany

Abstract

Given its increasing global prevalence, Alzheimer's disease (AD) has become a major public health challenge worldwide. The symptomatic treatments available for AD have shown no significant efficacy, and no disease-modifying interventions are capable of slowing the progression of the disorder. The potential of lifestyle-related factors, including diet, is increasingly recognized as an important consideration in the primary prevention of AD. Numerous mechanisms potentially underlying neuroprotective effects of bioactive components contained in tea, such as (–)-epigallocatechin-3-gallate, as well as their preventive efficacy against AD, have been elucidated in preclinical studies. However, in contrast to the abundance of mechanistic findings in animals, clinical results demonstrating efficacy in humans are scarce. While epidemiological studies have provided some evidence indicating that green tea consumption is associated with a reduced risk of age-related cognitive decline and AD, a causal relationship cannot be established on the basis of these observations. The clinical evidence regarding preventive or therapeutic effects of green tea and its bioactive components is unsatisfactory. A role of green tea in the prevention of AD cannot be recommended until well-designed, randomized, placebo-controlled clinical trials using standardized formulations confirm the purported beneficial effects of green tea.

Keywords: Prevention, Neurodegeneration, Alzheimer's disease, Green tea, Epigallocatechin gallate

References(84)

[1]

K.W. Lange, B.J. Sahakian, N.P. Quinn, et al., Comparison of executive and visuospatial memory function in Huntington's disease and dementia of Alzheimer type matched for degree of dementia, J. Neurol. Neurosurg. Psychiatry 58 (1995) 598-606. https://doi.org/10.1136/jnnp.58.5.598.
DOI Google Scholar
[2]

P. Scheltens, K. Blennow, M.M.B. Breteler, et al., Alzheimer's disease, Lancet 388 (2016) 505-517. https://doi.org/10.1016/S0140-6736(15)01124-1.
DOI Google Scholar
[3]

D.A. Butterfield, C.M. Lauderback, Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress, Free Radic. Biol. Med. 32 (2002) 1050-1060. https://doi.org/10.1016/s0891-5849(02)00794-3.
DOI Google Scholar
[4]

L. Crews, E. Masliah, Molecular mechanisms of neurodegeneration in Alzheimer's disease, Hum. Mol. Genet. 19 (2010) R12-R20. https://doi.org/10.1093/hmg/ddq160.
DOI Google Scholar
[5]

H.W. Querfurth, F.M. LaFerla, Alzheimer's disease, N. Engl. J. Med. 362 (2010) 329-344. https://doi.org/10.1056/NEJMra0909142.
DOI Google Scholar
[6]

M.J. Prince, F. Wu, Y. Guo, et al., The burden of disease in older people and implications for health policy and practice, Lancet 385 (2015) 549-562. https://doi.org/10.1016/S0140-6736(14)61347-7.
DOI Google Scholar
[7]

K.W. Lange, Diet, exercise, and mental disorders - public health challenges of the future, Mov. Nutr. Health Dis. 2 (2018) 39-59. https://doi.org/10.5283/MNHD.12.
DOI Google Scholar
[8]

E. Sohn, How the evidence stacks up for preventing Alzheimer's disease, Nature 559 (2018) S18-S20. https://doi.org/10.1038/d41586-018-05724-7.
DOI Google Scholar
[9]

J.T. Yu, W. Xu, C.C. Tan, et al., Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials, J. Neurol. Neurosurg. Psychiatry 91 (2020) 1201-1209. https://doi.org/10.1136/jnnp-2019-321913.
DOI Google Scholar
[10]

R.F.A.G. de Bruijn, M.J. Bos, M.L.P. Portegies, et al., The potential for prevention of dementia across two decades: the prospective, population-based Rotterdam study, BMC Med. 13 (2015) 132. https://doi.org/10.1186/s12916-015-0377-5.
DOI Google Scholar
[11]

F.E. Matthews, A. Arthur, L.E. Barnes, et al., A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study Ⅰ and Ⅱ, Lancet 382 (2013) 1405-1412. https://doi.org/10.1016/S0140-6736(13)61570-6.
DOI Google Scholar
[12]

C. Qiu, E. von Strauss, L. Bäckman, et al., Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden, Neurology 80 (2013) 1888-1894. https://doi.org/10.1212/WNL.0b013e318292a2f9.
DOI Google Scholar
[13]

C.L. Satizabal, A.S. Beiser, V. Chouraki, et al., Incidence of dementia over hree decades in the Framingham Heart Study, N. Engl. J. Med. 374 (2016) 523-532. https://doi.org/10.1056/NEJMoa1504327.
DOI Google Scholar
[14]

S. Norton, F.E. Matthews, D.E. Barnes, et al., Potential for primary prevention of Alzheimer's disease: an analysis of population-based data, Lancet Neurol. 13 (2014) 788-794. https://doi.org/10.1016/S1474-4422(14)70136-X.
DOI Google Scholar
[15]

Y.T. Wu, L. Fratiglioni, F.E. Matthews, et al., Dementia in western Europe: epidemiological evidence and implications for policy making, Lancet Neurol. 15 (2016) 116-124. https://doi.org/10.1016/S1474-4422(15)00092-7.
DOI Google Scholar
[16]

D.R. Gustafson, M. Clare Morris, N. Scarmeas, et al., New perspectives on Alzheimer's disease and nutrition, J. Alzheimers. Dis. 46 (2015) 1111-1127. https://doi.org/10.3233/JAD-150084.
DOI Google Scholar
[17]

S. Huhn, S. Kharabian Masouleh, M. Stumvoll, et al., Components of a Mediterranean diet and their impact on cognitive functions in aging, Front. Aging Neurosci. 7 (2015) 132. https://doi.org/10.3389/fnagi.2015.00132.
DOI Google Scholar
[18]

Y. Gu, J.A. Luchsinger, Y. Stern, et al., Mediterranean diet, inflammatory and metabolic biomarkers, and risk of Alzheimer's disease, J. Alzheimers. Dis. 22 (2010) 483-492. https://doi.org/10.3233/JAD-2010-100897.
DOI Google Scholar
[19]

K.W. Lange, Mediterranean diet and Alzheimer's disease, Mov. Nutr. Health Dis. 3 (2019) 1-15. https://doi.org/10.5283/MNHD.13.
DOI Google Scholar
[20]

K.W. Lange, K.M. Lange, E. Makulska-Gertruda, et al., Ketogenic diets and Alzheimer's disease, Food Sci. Hum. Wellness 6 (2017) 1-9. https://doi.org/10.1016/j.fshw.2016.10.003.
DOI Google Scholar
[21]

K.W. Lange, J. Guo, S. Kanaya, et al., Medical foods in Alzheimer's disease, Food Sci. Hum. Wellness 8 (2019) 1-7. https://doi.org/10.1016/j.fshw.2019.02.002.
DOI Google Scholar
[22]

K.W. Lange, Y. Nakamura, N. Chen, et al., Diet and medical foods in Parkinson's disease, Food Sci. Hum. Wellness 8 (2019) 83-95. https://doi.org/10.1016/j.fshw.2019.03.006.
DOI Google Scholar
[23]

W. Marx, G. Moseley, M. Berk, et al., Nutritional psychiatry: the present state of the evidence, Proc. Nutr. Soc. 76 (2017) 427-436. https://doi.org/10.1017/S0029665117002026.
DOI Google Scholar
[24]

K.W. Lange, Do food bioactives play a role in attention-deficit/hyperactivity disorder?, J. Food Bioact. 4 (2018) 1-7. https://doi.org/10.31665/JFB.2018.4160.
DOI Google Scholar
[25]

K.W. Lange, S. Li, Resveratrol, pterostilbene, and dementia, Biofactors 44 (2018) 83-90. https://doi.org/10.1002/biof.1396.
DOI Google Scholar
[26]

K.W. Lange, Red wine, resveratrol, and Alzheimer's disease, Mov. Nutr. Health Dis. (2018) 31-38. https://doi.org/10.5283/mnhd.11.
DOI Google Scholar
[27]

S. Srinivasan, L. Pari, Ameliorative effect of diosmin, a citrus flavonoid against streptozotocin-nicotinamide generated oxidative stress induced diabetic rats, Chem. Biol. Interact. 195 (2012) 43-51. https://doi.org/10.1016/j.cbi.2011.10.003.
DOI Google Scholar
[28]

Y. Miyake, K. Yamamoto, Y. Morimitsu, et al., Isolation of C-glucosylflavone from lemon peel and antioxidative activity of flavonoid compounds in lemon fruit, J. Agric. Food Chem. 45(12) (1997) 4619-4623. http://dx.doi.org/10.1021/jf970498x.
DOI Google Scholar
[29]

K.W. Lange, Omega-3 fatty acids and mental health, Glob. Health J. 4 (2020) 18-30. https://doi.org/10.1016/j.glohj.2020.01.004.
DOI Google Scholar
[30]

K.W. Lange, K.M. Lange, Y. Nakamura, et al., Is there a role of gut microbiota in mental health?, J. Food Bioact. 9 (2020) 4-9. https://doi.org/10.31665/JFB.2020.9213.
DOI Google Scholar
[31]

K.W. Lange, K.M. Lange, Y. Nakamura, et al., Do natural antioxidants play a role in Alzheimer's disease?, J. Food Bioact. 11 (2020) 2-10. https://doi.org/10.31665/JFB.2020.11233.
DOI Google Scholar
[32]

K.W. Lange, Micronutrients and diets in the treatment of attention-deficit/hyperactivity disorder: chances and pitfalls, Front. Psychiatry 11 (2020) 102. https://doi.org/10.3389/fpsyt.2020.00102.
DOI Google Scholar
[33]

K.W. Lange, Y. Nakamura, K.M. Lange, The use of probiotics in depression, J. Food Bioact. 12 (2020) 3-8. https://doi.org/10.31665/JFB.2020.12244.
DOI Google Scholar
[34]

K.W. Lange, Y. Nakamura, K.M. Lange, et al., Tea and depression, Food Sci. Hum. Well. 11 (2022) 476-482.
DOI Google Scholar
[35]

R. Gaudreault, N. Mousseau, Mitigating Alzheimer's disease with natural polyphenols: a review, Curr. Alzheimer Res. 16 (2019) 529-543. https://doi.org/10.2174/1567205016666190315093520.
DOI Google Scholar
[36]

D. Commenges, V. Scotet, S. Renaud, et al., Intake of flavonoids and risk of dementia, Eur. J. Epidemiol. 16 (2000) 357-363. https://doi.org/10.1023/a:1007614613771.
DOI Google Scholar
[37]

M.J. Engelhart, M.I. Geerlings, A. Ruitenberg, et al., Dietary intake of antioxidants and risk of Alzheimer disease, JAMA 287 (2002) 3223-3229. https://doi.org/10.1001/jama.287.24.3223.
DOI Google Scholar
[38]

T.M. Holland, P. Agarwal, Y. Wang, et al., Dietary flavonols and risk of Alzheimer dementia, Neurology 94 (2020) e1749-e1756. https://doi.org/10.1212/WNL.0000000000008981.
DOI Google Scholar
[39]

S.Q. Chen, Z.S. Wang, Y.X. Ma, et al., Neuroprotective effects and mechanisms of tea bioactive components in neurodegenerative diseases, Molecules 23 (2018) 512. https://doi.org/10.3390/molecules23030512.
DOI Google Scholar
[40]

S.A. Mandel, T. Amit, L. Kalfon, et al., Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG), J. Alzheimers. Dis. 15 (2008) 211-222. https://doi.org/10.3233/jad-2008-15207.
DOI Google Scholar
[41]

S. Sang, J.D. Lambert, C.T. Ho, et al., The chemistry and biotransformation of tea constituents, Pharmacol. Res. 64 (2011) 87-99. https://doi.org/10.1016/j.phrs.2011.02.007.
DOI Google Scholar
[42]

C.S. Yang, E. Pan, The effects of green tea polyphenols on drug metabolism, Expert Opin. Drug Metab. Toxicol. 8 (2012) 677-689. https://doi.org/10.1517/17425255.2012.681375.
DOI Google Scholar
[43]

G. Esquerda-Canals, L. Montoliu-Gaya, J. Güell-Bosch, et al., Mouse models of Alzheimer's disease, J. Alzheimers. Dis. 57 (2017) 1171-1183. https://doi.org/10.3233/JAD-170045.
DOI Google Scholar
[44]

A. Myers, P. McGonigle, Overview of transgenic mouse models for Alzheimer's disease, Curr. Protoc. Neurosci. 89 (2019) e81. https://doi.org/10.1002/cpns.81.
DOI Google Scholar
[45]

M. Newman, E. Ebrahimie, M. Lardelli, Using the zebrafish model for Alzheimer's disease research, Front. Genet. 5 (2014) 189. https://doi.org/10.3389/fgene.2014.00189.
DOI Google Scholar
[46]

S. Bouleau, H. Tricoire, Drosophila models of Alzheimer's disease: advances, limits, and perspectives, J. Alzheimers. Dis. 45 (2015) 1015-1038. https://doi.org/10.3233/JAD-142802.
DOI Google Scholar
[47]

S.B. Hannan, N.M. Dräger, T.M. Rasse, et al., Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models, J. Neurochem. 137 (2016) 12-25. https://doi.org/10.1111/jnc.13532.
DOI Google Scholar
[48]

L. Tsuda, Y.M. Lim, Alzheimer's disease model system using Drosophila, Adv. Exp. Med. Biol. 1076 (2018) 25-40. https://doi.org/10.1007/978-981-13-0529-0_3.
DOI Google Scholar
[49]

K. Rezai-Zadeh, D. Shytle, N. Sun, et al., Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice, J. Neurosci. 25 (2005) 8807-8814. https://doi.org/10.1523/JNEUROSCI.1521-05.2005.
DOI Google Scholar
[50]

K. Rezai-Zadeh, G.W. Arendash, H. Hou, et al., Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice, Brain Res. 1214 (2008) 177-187. https://doi.org/10.1016/j.brainres.2008.02.107.
DOI Google Scholar
[51]

S. Mandel, M.B.H. Youdim, Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases, Free Radic. Biol. Med. 37 (2004) 304-317. https://doi.org/10.1016/j.freeradbiomed.2004.04.012.
DOI Google Scholar
[52]

K. Youn, C.T. Ho, M. Jun, Multi-faceted neuroprotective effects of (–)-epigallocatechin-3-gallate (EGCG) in Alzheimer's disease: an overview of pre-clinical studies focused on β-amyloid peptide, Food Sci. Hum. Well. 11 (2022) 483-493.
DOI Google Scholar
[53]

K.W. Lange, Utility of animal models of Alzheimer's disease in food bioactive research, J. Food Bioact 13 (2021) 12-19.
DOI Google Scholar
[54]

A. Bilkei-Gorzo, Genetic mouse models of brain ageing and Alzheimer's disease, Pharmacol. Ther. 142 (2014) 244-257. https://doi.org/10.1016/j.pharmthera.2013.12.009.
DOI Google Scholar
[55]

P. Willner, Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case, Prog. Neuropsychopharmacol. Biol. Psychiatry 10 (1986) 677-690. https://doi.org/10.1016/0278-5846(86)90051-5.
DOI Google Scholar
[56]

J.L. Cummings, T. Morstorf, K. Zhong, Alzheimer's disease drug-development pipeline: few candidates, frequent failures, Alzheimers. Res. Ther. 6 (2014) 37. https://doi.org/10.1186/alzrt269.
DOI Google Scholar
[57]

A. Banik, R.E. Brown, J. Bamburg, et al., Translation of pre-clinical studies into successful clinical trials for Alzheimer's disease: what are the roadblocks and how can they be overcome?, J. Alzheimers. Dis. 47 (2015) 815-843. https://doi.org/10.3233/JAD-150136.
DOI Google Scholar
[58]

E. Drummond, T. Wisniewski, Alzheimer's disease: experimental models and reality, Acta Neuropathol. 133 (2017) 155-175. https://doi.org/10.1007/s00401-016-1662-x.
DOI Google Scholar
[59]

Y. Tomata, K. Sugiyama, Y. Kaiho, et al., Green tea consumption and the risk of incident dementia in elderly Japanese: the Ohsaki Cohort 2006 Study, Am. J. Geriatr. Psychiatry 24 (2016) 881-889. https://doi.org/10.1016/j.jagp.2016.07.009.
DOI Google Scholar
[60]

S. Kakutani, H. Watanabe, N. Murayama, Green tea intake and risks for dementia, Alzheimer's disease, mild cognitive impairment, and cognitive impairment: a systematic review, Nutrients 11 (2019) 1165. https://doi.org/10.3390/nu11051165.
DOI Google Scholar
[61]

D.L. Sackett, Bias in analytic research, J. Chronic Dis. 32 (1979) 51-63. https://doi.org/10.1016/0021-9681(79)90012-2.
DOI Google Scholar
[62]

S. Kuriyama, A. Hozawa, K. Ohmori, et al., Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1, Am. J. Clin. Nutr. 83 (2006) 355-361. https://doi.org/10.1093/ajcn/83.2.355.
DOI Google Scholar
[63]

M. Noguchi-Shinohara, S. Yuki, C. Dohmoto, et al., Consumption of green tea, but not black tea or coffee, is associated with reduced risk of cognitive decline, PLoS One 9 (2014) e96013. https://doi.org/10.1371/journal.pone.0096013.
DOI Google Scholar
[64]

W. Shen, Y. Xiao, X. Ying, et al., Tea consumption and cognitive impairment: a cross-sectional study among Chinese elderly, PLoS One 10 (2015) e0137781. https://doi.org/10.1371/journal.pone.0137781.
DOI Google Scholar
[65]

K. Kitamura, Y. Watanabe, K. Nakamura, et al., Modifiable factors associated with cognitive impairment in 1143 Japanese outpatients: the project in Sado for total health (PROST), Dement. Geriatr. Cogn. Dis. Extra 6 (2016) 341-349. https://doi.org/10.1159/000447963.
DOI Google Scholar
[66]

C.Y. Lee, Y. Sun, H.J. Lee, et al., Modest overweight and healthy dietary habits reduce risk of dementia: a nationwide survey in Taiwan, J. Prev. Alzheimers. Dis. 4 (2017) 37-43. https://doi.org/10.14283/jpad.2016.123.
DOI Google Scholar
[67]

K. Fischer, D. van Melo Lent, S. Wolfsgruber, et al., Prospective associations between single foods, Alzheimer's dementia and memory decline in the elderly, Nutrients 10 (2018) 852. https://doi.org/10.3390/nu10070852.
DOI Google Scholar
[68]

H. Xu, Y. Wang, Y. Yuan, et al., Gender differences in the protective effects of green tea against amnestic mild cognitive impairment in the elderly Han population, Neuropsychiatr. Dis. Treat. 14 (2018) 1795-1801. https://doi.org/10.2147/NDT.S165618.
DOI Google Scholar
[69]

S.K. Park, I.C. Jung, W.K. Lee, et al., A combination of green tea extract and L-theanine improves memory and attention in subjects with mild cognitive impairment: a double-blind placebo-controlled study, J. Med. Food 14 (2011) 334-343. https://doi.org/10.1089/jmf.2009.1374.
DOI Google Scholar
[70]

K. Ide, H. Yamada, N. Takuma, et al., Effects of green tea consumption on cognitive dysfunction in an elderly population: a randomized placebo-controlled study, Nutr. J. 15 (2016) 49. https://doi.org/10.1186/s12937-016-0168-7.
DOI Google Scholar
[71]

J.K. Lin, C.L. Lin, Y.C. Liang, et al., Survey of catechins, gallic acid, and methylxanthines in green, oolong, Pu-erh, and black teas, J. Agric. Food Chem. 46 (1998) 3635-3642. https://doi.org/10.1021/jf980223x.
DOI Google Scholar
[72]

Y.S. Lin, Y.J. Tsai, J.S. Tsay, et al., Factors affecting the levels of tea polyphenols and caffeine in tea leaves, J. Agric. Food Chem. 51 (2003) 1864-1873. https://doi.org/10.1021/jf021066b.
DOI Google Scholar
[73]

T. Suzuki, M. Pervin, S. Goto, et al., Beneficial effects of tea and the green tea catechin epigallocatechin-3-gallate on obesity, Molecules 21 (2016) 1305. https://doi.org/10.3390/molecules21101305.
DOI Google Scholar
[74]

N. Miyoshi, M. Pervin, T. Suzuki, et al., Green tea catechins for well-being and therapy: prospects and opportunities, Bot. Targets Ther. (2015) 85-96. https://doi.org/10.2147/BTAT.S91784.
DOI Google Scholar
[75]

C.S. Yang, X. Wang, G. Lu, et al., Cancer prevention by tea: animal studies, molecular mechanisms and human relevance, Nat. Rev. Cancer 9 (2009) 429-439. https://doi.org/10.1038/nrc2641.
DOI Google Scholar
[76]

A. Mähler, S. Mandel, M. Lorenz, et al., Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?, EPMA J. 4 (2013) 5. https://doi.org/10.1186/1878-5085-4-5.
DOI Google Scholar
[77]

E. Mancini, C. Beglinger, J. Drewe, et al., Green tea effects on cognition, mood and human brain function: a systematic review, Phytomedicine 34 (2017) 26-37. https://doi.org/10.1016/j.phymed.2017.07.008.
DOI Google Scholar
[78]

A. Schmidt, F. Hammann, B. Wölnerhanssen, et al., Green tea extract enhances parieto-frontal connectivity during working memory processing, Psychopharmacology (Berl) 231 (2014) 3879-3888. https://doi.org/10.1007/s00213-014-3526-1.
DOI Google Scholar
[79]

A. Scholey, L.A. Downey, J. Ciorciari, et al., Acute neurocognitive effects of epigallocatechin gallate (EGCG), Appetite. 58 (2012) 767-770. https://doi.org/10.1016/j.appet.2011.11.016.
DOI Google Scholar
[80]

K. Nakagawa, T. Miyazawa, Absorption and distribution of tea catechin, (–)-epigallocatechin-3-gallate, in the rat, J. Nutr. Sci. Vitaminol. (Tokyo) 43 (1997) 679-684. https://doi.org/10.3177/jnsv.43.679.
DOI Google Scholar
[81]

L. Chen, M.J. Lee, H. Li, et al., Absorption, distribution, elimination of tea polyphenols in rats, Drug Metab. Dispos. 25 (1997) 1045-1050.
Google Scholar
[82]

F. Panza, V. Solfrizzi, M.R. Barulli, et al., Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review, J. Nutr. Health Aging 19 (2015) 313-328. https://doi.org/10.1007/s12603-014-0563-8.
DOI Google Scholar
[83]

G.L. Bowman, L.C. Silbert, D. Howieson, et al., Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging, Neurology 78 (2012) 241-249. https://doi.org/10.1212/WNL.0b013e3182436598.
DOI Google Scholar
[84]

W.N. Whiteley, S. Anand, S.I. Bangdiwala, et al., Are large simple trials for dementia prevention possible?, Age Ageing 49 (2020) 154-160. https://doi.org/10.1093/ageing/afz152.
DOI Google Scholar
Publication history
Copyright
Rights and permissions

Publication history

Received: 23 February 2020
Revised: 29 March 2021
Accepted: 31 March 2021
Published: 28 April 2022
Issue date: July 2022

Copyright

© 2022 Beijing Academy of Food Sciences. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.

Rights and permissions

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Return